In summary, our findings revealed the novel molecular pathway ADAR1/METTL3/ARHGAP5 connecting ADAR1, METTL3 and YTHDF1 (Figure 8), which may indicate ADAR1 or METTL3 as prognostic and therapeutical targets for the treatment of breast cancer. This evidence concerns the gene ARHGAP5 and breast carcinoma.